Save time and jump to the most important pieces.
8-K - Calidi Biotherapeutics, Inc. (0001855485) (Filer)
424B3 - Calidi Biotherapeutics, Inc. (0001855485) (Filer)
8-K - Calidi Biotherapeutics, Inc. (0001855485) (Filer)
SC 13G/A - Calidi Biotherapeutics, Inc. (0001855485) (Subject)
SC 13G/A - Calidi Biotherapeutics, Inc. (0001855485) (Subject)
SC 13G/A - Calidi Biotherapeutics, Inc. (0001855485) (Subject)
4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)
4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)
4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)
Business combination transaction with First Light Acquisition Group, a special purpose acquisition company, completed on September 12, 2023 Gross proceeds made available to Calidi Biotherapeutics from transaction total approximately $28 million, including funds held in First Light Acquisition Group's trust account before deducting transaction expenses and debt repayments In addition, Calidi secured a forward purchase agreement for up to $10 million with a consortium including Meteora Capital LLC, Great Point Capital LLC, and Funicular Funds, LP and intends to enter into a purchase agreement with Lincoln Park Capital Fund, LLC for up to $50 million; proceeds to extend Calidi's cash runway
Business combination transaction with Calidi Biotherapeutics anticipated to be completed on September 12, 2023 Gross proceeds made available to Calidi Biotherapeutics from transaction will total approximately $28 million, including funds held in First Light Acquisition Group's trust account before deducting transaction expenses and debt repayments In addition, Calidi secured a forward purchase agreement for up to $10 million with a consortium including Meteora Capital LLC, Great Point Capital LLC, and Funicular Funds, LP Listed company to be named Calidi Biotherapeutics, Inc. Common stock and warrants approved for listing on the New York Stock Exchange American under the ticker symbols
NEW YORK, Aug. 22, 2023 (GLOBE NEWSWIRE) -- First Light Acquisition Group, Inc. (NYSE:FLAG) ("FLAG") today announced that it convened and then adjourned, without conducting any other business, its virtual Special Meeting of Stockholders to August 24, 2023 at 10:30 a.m., Eastern time (the "Special Meeting"). The adjourned Special Meeting will be held via the same live webcast at https://www.cstproxy.com/firstlightacquisition/2023. The Special Meeting is being held to consider and vote on, among other things, the business combination transaction between FLAG and Calidi Biotherapeutics, Inc. ("Calidi"), pursuant to an Agreement and Plan of Merger, dated January 9, 203, as amended, by and amo
Business combination transaction with Calidi Biotherapeutics anticipated to be completed on September 12, 2023 Gross proceeds made available to Calidi Biotherapeutics from transaction will total approximately $28 million, including funds held in First Light Acquisition Group's trust account before deducting transaction expenses and debt repaymentsIn addition, Calidi secured a forward purchase agreement for up to $10 million with a consortium including Meteora Capital LLC, Great Point Capital LLC, and Funicular Funds, LPListed company to be named Calidi Biotherapeutics, Inc.Common stock and warrants approved for listing on the New York Stock Exchange American under the ticker symbols "CLDI" a
-8K Filing
Gainers Axcella Health Inc. (NASDAQ:AXLA) shares climbed 196% to $0.3335 after the company announced it was granted a patent for long COVID fatigue treatment. Tivic Health Systems, Inc. (NASDAQ:TIVC) gained 73.4% to $3.37 after falling 11% on Monday. Tivic Health Systems inked a pact to make its products available on AmerisourceBergen’s third-party marketplace. iCoreConnect Inc. (NASDAQ:ICCT) shares gained 70.4% to $2.7089 after dipping 20% on Monday. LifeVantage Corporation (NASDAQ:LFVN) gained 28.6% to $6.62 after the company posted fourth-quarter results and declared a special one-time cash dividend of $0.40 per share of common stock. EBET, Inc. (NASDAQ:EBET) rose 28% to $0.0501.